Associated Papers
Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.
Li J et al.
Discover Oncology, 2025
40053265 (PubMed )
Supplement: 12672_2025_2008_MOESM1_ESM.xlsx › Table_S2
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
36910641 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S8
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_2.xlsx › EGFR_Mutations
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
34788622 (PubMed )
Supplement: NIHMS1757901-supplement-2.xlsx › SNVs_indels
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.
Pleasance E et al.
Nature Cancer, 2020
35121966 (PubMed )
Supplement: 43018_2020_50_MOESM3_ESM.xlsx › Supplementary_Table_5
Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.
Marchetti A et al.
Plos One, 2012
22848739 (PubMed )
Supplement: pone.0042164.s003.xls › Table_S2
Select a paper to view details